The Dako PD-L1 IHC 22C3 pharmDx Interpretation Training Program
AdobeStock

Triple-Negative Breast Cancer (TNBC)

PD-L1 is a proven biomarker in triple-negative breast cancer. Learn how to evaluate and score PD-L1 expression using PD-L1 IHC 22C3 pharmDx and the Combined Positive Score (CPS).

AdobeStock

Head and Neck Squamous Cell Carcinoma (HNSCC)

PD-L1 is a proven biomarker in head and neck squamous cell carcinoma (HNSCC). Learn how to evaluate and score PD-L1 expression using PD-L1 IHC 22C3 pharmDx and the Combined Positive Score (CPS).

AdobeStock

Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

PD-L1 is a proven biomarker in gastric or gastroesophageal junction (GEJ) adenocarcinoma. Learn how to evaluate and score PD-L1 expression using PD-L1 IHC 22C3 pharmDx and the Combined Positive Score (CPS).

AdobeStock

Cervical Cancer

PD-L1 is a proven biomarker in cervical cancer. Learn how to evaluate and score PD-L1 expression using PD-L1 IHC 22C3 pharmDx and the Combined Positive Score (CPS).

AdobeStock

Urothelial Carcinoma (UC)

PD-L1 is a proven biomarker in urothelial carcinoma. Learn how to evaluate and score PD-L1 expression using PD-L1 IHC 22C3 pharmDx and the Combined Positive Score (CPS).

AdobeStock

Esophageal Squamous Cell Carcinoma (ESCC)

PD-L1 is a proven biomarker in esophageal squamous cell carcinoma (ESCC). Learn how to evaluate and score PD-L1 expression using PD-L1 IHC 22C3 pharmDx and the Combined Positive Score (CPS).

D63233/02